Aspira Women's Health Inc. (AWHL)

Market Cap	788.75K
Revenue (ttm)	9.18M
Net Income (ttm)	-13.09M
Shares Out	29.76M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	422,477
Average Volume	1,416,040
Open	0.0320
Previous Close	0.0300
Day's Range	0.0225 - 0.0320
52-Week Range	0.0770 - 3.5700
Beta	2.01
RSI	23.28
Earnings Date	May 20, 2025

About Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeter...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1993
• Employees: 66
• Stock Exchange: OTCMKTS
• Ticker Symbol: AWHL

Financial Performance

In 2024, Aspira Women's Health's revenue was $9.18 million, an increase of 0.31% compared to the previous year's $9.15 million. Losses were -$13.09 million, -21.55% less than in 2023.